ABCL635's Phase 2 efficacy readout in postmenopausal vasomotor symptoms will determine whether AbCellera's antibody platform can compete with approved NK3R antagonists

Bull

A positive readout would show statistically significant and clinically meaningful reductions in moderate-to-severe hot flash frequency and severity versus placebo, with a clean safety profile and no hepatotoxicity signals, consistent with the favorable Phase 1 pharmacodynamics. This would validate AbCellera's NK3R-targeting antibody approach as differentiated from small-molecule NK3R antagonists, support advancement into a pivotal trial, and meaningfully re-rate the company from platform-stage to late-stage clinical asset holder.

Bear

The most likely failure modes are insufficient efficacy — inadequate suppression of hot flash frequency or severity that does not meet pre-specified endpoints despite the promising testosterone biomarker signal seen in Phase 1 — or the emergence of tolerability or liver safety signals at the doses required for clinical effect. A modest or inconsistent efficacy signal in the 80-patient Phase 2 cohort could also leave the program in an ambiguous state, undermining confidence in the antibody modality versus the well-characterized small-molecule NK3R competitors.